| A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs D Rea, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, ... Blood, The Journal of the American Society of Hematology 138 (21), 2031-2041, 2021 | 198 | 2021 |
| Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial M Trněný, T Lamy, J Walewski, D Belada, J Mayer, J Radford, W Jurczak, ... The Lancet Oncology 17 (3), 319-331, 2016 | 171 | 2016 |
| Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities AP Kater, C Owen, C Moreno, G Follows, T Munir, MD Levin, O Benjamini, ... NEJM Evidence 1 (7), EVIDoa2200006, 2022 | 111 | 2022 |
| Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL A Hochhaus, D Réa, C Boquimpani, Y Minami, JE Cortes, TP Hughes, ... Leukemia 37 (3), 617-626, 2023 | 44 | 2023 |
| Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with … A Hochhaus, C Boquimpani, D Rea, Y Minami, E Lomaia, S Voloshin, ... Blood, The Journal of the American Society of Hematology 136 (Supplement_2 …, 2020 | 33 | 2020 |
| First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+ Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+ O) for … T Munir, C Moreno, C Owen, GA Follows, O Benjamini, A Janssens, ... Blood 138 (Supplement 1), 70-70, 2021 | 30 | 2021 |
| Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+ Ven) Versus Chlorambucil Plus … CU Niemann, T Munir, C Moreno, C Owen, GA Follows, O Benjamini, ... Blood 140 (Supplement 1), 228-230, 2022 | 27 | 2022 |
| Изменения системы крови в клинической практике АН Богданов, СВ Волошин, ТГ Кулибаба, ВВ Тыренко, СГ Щербак, ... Изменения системы крови в клинической практике, 2017 | 25 | 2017 |
| Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid … MJ Mauro, Y Minami, D Rea, A Hochhaus, E Lomaia, S Voloshin, ... Blood 138 (Supplement 1), 310-310, 2021 | 23 | 2021 |
| Биологические характеристики и лечение острого промиелоцитарного лейкоза ВГ Савченко, ЕН Паровичникова, МП Исаев, ИА Демидова, ... Терапевтический архив 70 (7), 5-11, 1998 | 23 | 1998 |
| Клиническое значение некоторых цитокинов при злокачественных неходжкинских лимфомах НБ Серебряная, АА Новик, СВ Волошин, АВ Новицкий Цитокины и воспаление 1 (3), 21-26, 2002 | 21 | 2002 |
| Результаты проводимых в течение 7 лет клинических исследований по лечению острых миелоидных лейкозов взрослых ВГ Савченко, ЕН Паровичникова, ГА Клясова, ВГ Исаев, АВ Пивник, ... Терапевтический архив 71 (7), 13-20, 1999 | 21 | 1999 |
| Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study T Munir, C Moreno, C Owen, G Follows, O Benjamini, A Janssens, ... Journal of Clinical Oncology 41 (21), 3689-3699, 2023 | 18 | 2023 |
| Infrared Spectroscopy of Blood Serum from Patients with Multiple Myeloma LV Plotnikova, MO Kobeleva, EV Borisov, AD Garifullin, AV Povolotskaya, ... Cell and Tissue Biology 13, 130-135, 2019 | 17 | 2019 |
| Рекомендации по диагностике и терапии хронического миелолейкоза КМ Абдулкадыров, АГ Туркина, НД Хорошко, ВА Шуваев, ... | 15 | 2013 |
| Заготовка трансплантата для аутологичной трансплантации гемопоэтических стволовых клеток онкогематологическим больным: частота и причины неудачных сборов СВ Грицаев, АА Кузяева, СВ Волошин, ЖВ Чубукина, ВА Балашова, ... РМЖ. Приложение. Онкология 4 (1), 30-35, 2013 | 13 | 2013 |
| Characterization of the infrared spectra of serum from patients with multiple myeloma L Plotnikova, A Polyanichko, T Nosenko, M Uspenskaya, A Garifullin, ... AIP Conference proceedings 1760 (1), 2016 | 12 | 2016 |
| Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open … CU Niemann, T Munir, C Moreno, C Owen, GA Follows, O Benjamini, ... The Lancet Oncology 24 (12), 1423-1433, 2023 | 11 | 2023 |
| Молекулярно-генетические маркеры и особенности течения эссенциальной тромбоцитемии АА Жернякова, ИС Мартынкевич, ВА Шуваев, ЛБ Полушкина, ... Клиническая онкогематология. Фундаментальные исследования и клиническая …, 2017 | 11* | 2017 |
| Significance of modified risk stratification mSmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma A Garifullin, S Voloshin, V Shuvaev, I Martynkevich, E Kleina, ... Blood 134, 5593, 2019 | 10 | 2019 |
Василий ШуваевФГБУ РосНИИГТ ФМБА РоссииVerified email at gematologya.com
